Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.63 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.52 |
| ▸ | KDM1A | O60341 | 3/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | PDE2A | O00408 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.46 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 2/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5655822 | 0.96 | GSK3B (0.59) | GSK3BSORT1HDAC1KDM1ACASP1 | |
| SCHEMBL4856282 | 0.90 | GSK3B (0.69) | GSK3BHDAC1CASP1HDAC3HDAC4 | |
| SCHEMBL4848924 | 0.90 | GSK3B (0.59) | GSK3BSORT1CASP1ROCK2PRKCA | |
| SCHEMBL4856280 | 0.89 | GSK3B (0.75) | GSK3BHDAC1CASP1HDAC3HDAC4 | |
| SCHEMBL4856466 | 0.88 | GSK3B (0.64) | GSK3BHDAC1KDM1ACASP1HDAC3 | |
| SCHEMBL4853063 | 0.88 | GSK3B (0.59) | GSK3BCASP1PDE2ANAMPTROCK2 | |
| Trifluoroacetic Acid SCHEMBL5658704 | 0.88 | GSK3B (0.67) | GSK3BSORT1HDAC1CASP1HDAC3 | |
| Trifluoroacetic Acid SCHEMBL5657353 | 0.87 | GSK3B (0.58) | GSK3BSORT1HDAC1KDM1ACASP1 | |
| Trifluoroacetic Acid SCHEMBL5657173 | 0.87 | GSK3B (0.58) | GSK3BSORT1HDAC1KDM1ACASP1 | |
| SCHEMBL4848500 | 0.87 | GSK3B (0.62) | GSK3BHDAC1KDM1ACASP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7309701-B2 | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-12-18 | — | — | US | claimed |
| EP-1581505-B1 | PYRIDAZINONE DERIVATIVES AS GSK-3BETA INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-08-01 | — | — | EP | claimed |
| EP-1581505-A1 | PYRIDAZINONE DERIVATIVES AS GSK-3BETA INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2005-10-05 | — | — | EP | claimed |
| US-20040176377-A1 | Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-09-09 | — | — | US | claimed |
| WO-2004046117-A1 | PYRIDAZINONE DERIVATIVES AS GSK-3BETA INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-03 | — | — | WO | claimed |
| US-7462613-B2 | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-12-09 | — | — | US | disclosed |
| US-7462613-B2 | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-12-09 | — | — | US | disclosed |
| US-7462613-B2 | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-12-09 | — | — | US | disclosed |
| US-7309701-B2 | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-12-18 | — | — | US | disclosed |
| US-7309701-B2 | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-12-18 | — | — | US | disclosed |
| US-7309701-B2 | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-12-18 | — | — | US | disclosed |
| EP-1611121-B1 | PYRIDAZINONE DERIVATIVES AS CDK2-INHIBITORS | AVENTIS PHARMA SA (FR) | 2007-08-08 | — | — | EP | disclosed |
| EP-1581505-B1 | PYRIDAZINONE DERIVATIVES AS GSK-3BETA INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-08-01 | — | — | EP | disclosed |
| EP-1611121-A1 | PYRIDAZINONE DERIVATIVES AS CDK2-INHIBITORS | Aventis Pharma S.A. (FR) | 2006-01-04 | — | — | EP | disclosed |
| EP-1581505-A1 | PYRIDAZINONE DERIVATIVES AS GSK-3BETA INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2005-10-05 | — | — | EP | disclosed |
| US-20050026918-A1 | Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-02-03 | — | — | US | disclosed |
| US-20040176377-A1 | Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-09-09 | — | — | US | disclosed |
| WO-2004046117-A1 | PYRIDAZINONE DERIVATIVES AS GSK-3BETA INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-03 | — | — | WO | disclosed |
| WO-2004046130-A1 | PYRIDAZINONE DERIVATIVES AS CDK2-INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176377-A1 | Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | ADRA2C, ADRA1A, ADRA1B | GSK3B 3654/4885SORT1 4657/4885HDAC1 827/4885 |
| US-20050026918-A1 | Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | C5, ADRA2C, ADRA1A | GSK3B 3708/4885SORT1 4606/4885HDAC1 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.